+

WO2007014167A3 - Compositions for and methods of treating epithelial diseases with growth factors - Google Patents

Compositions for and methods of treating epithelial diseases with growth factors Download PDF

Info

Publication number
WO2007014167A3
WO2007014167A3 PCT/US2006/028699 US2006028699W WO2007014167A3 WO 2007014167 A3 WO2007014167 A3 WO 2007014167A3 US 2006028699 W US2006028699 W US 2006028699W WO 2007014167 A3 WO2007014167 A3 WO 2007014167A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
growth factors
treating epithelial
epithelial diseases
Prior art date
Application number
PCT/US2006/028699
Other languages
French (fr)
Other versions
WO2007014167A2 (en
Inventor
Kristen Pierce
Ge Wu
Aileen Zhou
William Roscoe
Stephen Doberstein
Original Assignee
Five Prime Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics, Inc. filed Critical Five Prime Therapeutics, Inc.
Publication of WO2007014167A2 publication Critical patent/WO2007014167A2/en
Publication of WO2007014167A3 publication Critical patent/WO2007014167A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to compositions and methods for treating epithelial diseases such as mucositis and inflammatory bowel disease in a subject. The invention also relates to long-acting therapeutic agents capable of promoting survival of an oral keratinocyte or an intestinal epithelial cell.
PCT/US2006/028699 2005-07-22 2006-07-24 Compositions for and methods of treating epithelial diseases with growth factors WO2007014167A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70206505P 2005-07-22 2005-07-22
US60/702,065 2005-07-22

Publications (2)

Publication Number Publication Date
WO2007014167A2 WO2007014167A2 (en) 2007-02-01
WO2007014167A3 true WO2007014167A3 (en) 2009-09-17

Family

ID=37683889

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/028699 WO2007014167A2 (en) 2005-07-22 2006-07-24 Compositions for and methods of treating epithelial diseases with growth factors

Country Status (1)

Country Link
WO (1) WO2007014167A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013025817A1 (en) 2011-08-15 2013-02-21 Children's Hospital Los Angeles Use of neuregulin-4 for treatment of inflammatory bowel disease and necrotizing enterocolitis
WO2019231860A1 (en) * 2018-05-27 2019-12-05 The Board Of Trustees Of The Leland Stanford Junior University Method for treating or preventing radiotherapy- and chemotherapy-associated oral mucositis using locally administered heparin binding epidermal growth factor like growth factor (hb-egf)
WO2016064998A1 (en) * 2014-10-21 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Promoting epithelial regeneration post tonsillectomy using heparin binding epidermal growth factor like growth factor
US10702586B2 (en) 2015-09-28 2020-07-07 Children's Hospital Los Angeles Methods for treating diseases mediated by ErbB4-positive pro-inflammatory macrophages
WO2020031204A1 (en) * 2018-08-08 2020-02-13 Sree Chitra Tirunal Institute For Medical Science And Technology Recombinant tgf α for wound healing purposes, and the process thereof
WO2021198369A1 (en) * 2020-03-31 2021-10-07 Panda Jonas Songhomitra Agents for use in the therapeutic or prophylactic treatment of retinal pigment epithelium associated diseases

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991012018A1 (en) * 1990-02-13 1991-08-22 Gropep Pty. Ltd. Method for treating intestinal diseases
WO1992003155A1 (en) * 1990-08-24 1992-03-05 Kabi Pharmacia Ab Product containing growth factor and glutamine and use of growth factor for the treatment of intestinal mucosa
WO1996037216A1 (en) * 1995-05-22 1996-11-28 Genentech, Inc. Method of administration of igf-i
WO1998011904A1 (en) * 1996-09-20 1998-03-26 Scientific Hospital Supplies International Limited Prevention of gastrointestinal damage
US6319899B1 (en) * 1997-09-17 2001-11-20 The Nemours Foundation Method and composition for the treatment of inflammatory bowel disease
US20030144202A1 (en) * 1996-10-15 2003-07-31 Amgen Inc. Uses of keratinocyte growth factor-2
US20030171267A1 (en) * 2000-04-12 2003-09-11 Rosen Craig A. Albumin fusion proteins
US20040136952A1 (en) * 2002-12-26 2004-07-15 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991012018A1 (en) * 1990-02-13 1991-08-22 Gropep Pty. Ltd. Method for treating intestinal diseases
WO1992003155A1 (en) * 1990-08-24 1992-03-05 Kabi Pharmacia Ab Product containing growth factor and glutamine and use of growth factor for the treatment of intestinal mucosa
WO1996037216A1 (en) * 1995-05-22 1996-11-28 Genentech, Inc. Method of administration of igf-i
WO1998011904A1 (en) * 1996-09-20 1998-03-26 Scientific Hospital Supplies International Limited Prevention of gastrointestinal damage
US20030144202A1 (en) * 1996-10-15 2003-07-31 Amgen Inc. Uses of keratinocyte growth factor-2
US6319899B1 (en) * 1997-09-17 2001-11-20 The Nemours Foundation Method and composition for the treatment of inflammatory bowel disease
US20030171267A1 (en) * 2000-04-12 2003-09-11 Rosen Craig A. Albumin fusion proteins
US20040136952A1 (en) * 2002-12-26 2004-07-15 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity

Also Published As

Publication number Publication date
WO2007014167A2 (en) 2007-02-01

Similar Documents

Publication Publication Date Title
IL187982A0 (en) Human placental collagen compositions, processes for their preparation, methods of their use and kits comprising the compositions
IL186814A0 (en) Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs and organisms
HUS1800021I1 (en) Human anti-il-23 antibodies, compositions, methods and uses
WO2007007173A3 (en) Human anti-madcam antibodies
CR20110470A (en) PROTEINS OF UNION TO IL-17
AU2006279280A8 (en) Methods and compositions for treating neurological disease
EP2197270B8 (en) Placental tissue grafts and improved methods of preparing and using the same
IL180600A0 (en) Compositions and methods of use for treatment of mammalian diseases
PL1809303T3 (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans
IL164079A0 (en) Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
HK1113689A1 (en) Novel cellular compositions and methods for their preparation
IL183435A (en) Lyophilized formulations of keratinocyte growth factor
EP1651053A4 (en) Compositions and methods relating to freezer-to-oven doughs
IL189078A0 (en) Antitumoral bioconjugates of hyaluronic acid or its derivatives obtained by indirect chemical conjugation
WO2006017134A3 (en) Preprimitive streak and mesendoderm cells
WO2007014167A3 (en) Compositions for and methods of treating epithelial diseases with growth factors
ZA200800448B (en) Methods and compositions for the prevention and treatment of inflammatory disease
EP1667730A4 (en) Compositions and methods for treating inflammatory lung disease
WO2005113747A3 (en) Multicellular tissue and organ culture systems
IL190841A0 (en) Pharmaceutical compositions and diagnostic methods for inflammatory skin diseases, disorders or conditions
ZA200801678B (en) Treatment of inflammatory bowel disease
ZA200805419B (en) Compositions and methods for preventing or treating inflammatory bowel disease
WO2005030927A3 (en) Methods and compositions for in vivo inflammation monitoring
EP2341147A3 (en) Preprimitive streak and mesendoderm cells
WO2006094134A3 (en) Kim-1 antibodies for treatment of th2-mediated conditions

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06800289

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06800289

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载